Fig. 7: Anticancer effects of ERO1A inhibition in TNBC syngeneic and xenograft-bearing mice. | Cell Death & Disease

Fig. 7: Anticancer effects of ERO1A inhibition in TNBC syngeneic and xenograft-bearing mice.

From: Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment

Fig. 7

A EN460 and I2 signal revealed by MALDI imaging in representative primary MDAMB231 breast tumor sections from CTRL or EN460 and I2-treated MDAMB231 tumor-bearing SCID mice. On the right, signal intensity in Optical density (OD) (N = 4, mean ± SEM, One-way ANOVA). B Bioluminescence signals of primary breast tumors from SCID mice which were injected subcutaneously with MDAMB231 cells. Mice-bearing tumors were treated six times with EN460, I2, or vehicle, and the luminescence in AU was detected at t = 0 (T1) and t = 7 days (T2). Below are the bioluminescence signals of tumors. C The graph shows the percentage in tumor growth compared to day 0 when mice were randomized before the treatment (N = 10, mean ± SEM, Two-way ANOVA). D Graph representing VEGFA levels in primary breast tumors (One-way ANOVA). E Venn diagram showing the results of a differential transcriptomic analysis, comparing two sets of sample treatments: EN460 vs. CTRL-treated and I2 vs. CTRL-treated tumors (N = 5). Each circle contains the upregulated and downregulated pathways identified in the respective comparisons. The pathways are taken from the Hallmark gene sets collection (MSigDB). The analysis focused on significantly regulated pathways (False Discovery Rate, FDR < 0.05). The intersection of the two sets reveals a common downregulation of pathways related to cellular proliferation. F The graph shows tumor growth caliper measurements of each mouse. G The graph shows tumor growth caliper measurements of the mean of the treated mice (N = 8, mean ± SEM, Two-way ANOVA). H Mouse weights during treatment. I Graph representing VEGFA levels in primary breast tumors (One-way ANOVA). L The graph shows the percentage of orthotopic E0071 breast tumor growth compared to day 0 when mice were randomized before treatment (N = 8, mean ± SEM, Two-way ANOVA). M Orthotopic E0071 breast tumors. Representative cytofluorimeter plots of a PD-L1+ subset of monocytic myeloid-derived suppressor cells (M-MDSC) and dot plots of quantification of PD-L1 expression (MFI) in M-MDSC (N = 4, unpaired t-test).

Back to article page